343 related articles for article (PubMed ID: 26191215)
1. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.
Wang YD; Su YJ; Li JY; Yao XC; Liang GJ
Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215
[TBL] [Abstract][Full Text] [Related]
2. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
3. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
6. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of cyclin-E(1) via proline-mTOR pathway is responsible for HGF-mediated G(1)/S progression in the primary culture of rat hepatocytes.
Oka K; Ohya-Shimada W; Mizuno S; Nakamura T
Biochem Biophys Res Commun; 2013 May; 435(1):120-5. PubMed ID: 23618858
[TBL] [Abstract][Full Text] [Related]
8. Mechanism study of isoflavones as an anti-retinoblastoma progression agent.
Wu Q; Bai H; Huang CL; Zhang Y; Zeng X; Wan H; Zuo W; Wang HY; Zeng YX; Wang YD
Oncotarget; 2017 Oct; 8(51):88401-88409. PubMed ID: 29179444
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
Chang WL; Hsu LC; Leu WJ; Chen CS; Guh JH
Oncotarget; 2015 Nov; 6(37):39806-20. PubMed ID: 26447757
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin inhibits the proliferation of endothelial cells in hemangioma by blocking the mTOR-FABP4 pathway.
Wang Y; Chen J; Tang W; Zhang Y; Li X
Biomed Pharmacother; 2017 Jan; 85():272-279. PubMed ID: 27914823
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
Chen Z; Yang H; Li Z; Xia Q; Nie Y
Biochem Biophys Res Commun; 2019 Aug; 516(3):726-732. PubMed ID: 31253398
[TBL] [Abstract][Full Text] [Related]
12. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
Tirado OM; Mateo-Lozano S; Notario V
Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone inhibits growth of human retinoblastoma cells via regulation of NF-κB inflammation signals.
Wang F; Liu Y; Bi Z
J Recept Signal Transduct Res; 2017 Feb; 37(1):94-99. PubMed ID: 27133446
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Effects of Gingerol in Retinoblastoma Cancer Cells (RB355 Cell Line) Are Mediated via Apoptosis Induction, Cell Cycle Arrest and Upregulation of PI3K/Akt Signaling Pathway.
Meng B; Ii H; Qu W; Yuan H
Med Sci Monit; 2018 Apr; 24():1980-1987. PubMed ID: 29615601
[TBL] [Abstract][Full Text] [Related]
19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
20. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
Khor ES; Wong PF
Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]